VIVUS : Third Phase 3 CONQUER (OB-303) Trial

Apr 22, 2008 - VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that it has completed enrollment in the final of three phase 3 studies of Qnexa(TM) in overweight and obese patients with co-morbidities including hypertension, dyslipidemia, or type 2 diabetes. The CONQUER study (OB-303) enrolled patients with a Body Mass Index ("BMI") ranging from 27 to 45 and at least two additional co-morbidities. The co-primary endpoints for this study are the mean percent weight loss and the percentage of subjects achieving weight loss of 5% or more... VIVUS' Press Release -